Timken (NYSE:TKR) reported quarterly earnings of $1.67 per share which beat the analyst consensus estimate of $1.34 by 24.63 percent. This is a 21.9 percent increase over earnings of $1.37 per share from the same period last year. The company reported quarterly sales of $1.15 billion which beat the analyst consensus estimate of $1.13 billion by 1.77 percent. This is a 8.19 percent increase over sales of $1.06 billion the same period last year.
BD Launches First-in-Human Trial Of Sirolimus Drug-Coated Balloon To Expand Treatment Options For Peripheral Arterial Disease
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, has announced the start of enrollment in a first-in-human trial of a peripheral sirolimus drug-coated balloon (DCB).
BD is a
